Entering Year #3 of the IVDR and MDR: ...the finish line in sight?

Swedish MedTech Regulatory Summit 21 May 2019

Oliver Bisazza, Director Regulations & Industrial Policy MedTech Europe

Schedule MedTech Europe from diagnosis to cure

MedTech Europe

1

Reminder: Our Advice Last Year* to Swedish Industry

1. RUN!

- > Timelines are tight! May 2020/2022 is vester a
- Do what you can, when you can, e.g., start with quality systems, houling, economic operators, etc.

2. ADAPT!

- Engage Notified Bodies! You may need to contact several, and they may not all be available
- Remember Delegated/Implymenting Acts and guidance. They'll come at <u>different</u> points in time

3. SMILE!

Yar trade associations are here to <u>help</u>!

*MedTech Europe presentation at the 21 March 2018 Regulatory Summit

IVDR/MDR Implementation Status: Critical

- On 15 April, MedTech Europe wrote to European Commission Vice-President Katainen, calling on the Commission to take immediate and decisive action to address an "issue of absolute urgency for patient care across Europe."
- Our underlying concern is that the new EU medtech regulatory system is not on-track to be "ready on time to ensure continued access of patients and healthcare systems to lifesaving and lifetransforming devices."

MedTech Europe from diagnosis to cure	
Mr. Jyski Kotalsvon Jode, Gropol, Investment and Competitiveness European Commission Rave dia La (2020 De - Unit Broade	A severe consequence of this is that European start-ups and SMEs, which represent 95% of the med device industry, are already turning to the United States, Chan and other regions to develop and rol-out th innovations and bring their related economic activity outside of Europa.
Prior via email Brussels, 15 April 2019	From the 58 existing Notified Bodies designated to operate under the Directives, only 1 has been designated to the MDR – a UK one. DG GROW expects not more than 12 Notified Bodies will be designated by the e
Re: Open letter on the implementation and readiness status of the new Medical Device Regulation	of year, 5 months before the deadline! This is way too late, insufficient and gives no guarantee that Notif Bodies would have enough capacity to ensure continued regulatory approval of devices by May 2020.
Dear Vice-President Katainen,	new Regulation attempts to provide some relief to the system through a 'grace period' and a 'warehous
I am writing to you regarding an issue of absolute urgency for patient the actions Exceeded for the ernal	clause. Unfortunately, since these mechanisms only work for a portion of medical devices currently availal
market at large. The medical device industry in Europe confirminat with time, ate activity the Europe	they just partially achieve their initial objective. Please refer to the Annex for details.
Commission, the new regulatory system will not be any on the new regulatory decess of portions and healthcare systems to life-saving and life-transforming lices. Our industry is prepared to submanic ut lifes to comply the new Mether device Regulation (MDR).	This situation is clearly untenable, and time has run out to build a functioning regulatory system. This se circumstances will profoundly disrupt the medical technology internal market and create yet another signifit "Cliff Edge" putting patient safety, healthcare services and EU healthcare environment in a major disarray.
However, we cannot do so. I new reg. Fory system is not ready to function. The deadline for the system to be fully operation is not 2 fay 202, the date of MDP uplication as the Commission continues to	The industry continues to support the implementation of the new regulation as a major step to guaran
suggest and in a the symbol of the symbol of the case of No. Symbol of the common of the symbol of t	patient safety and access to innovative medical solutions to alleviate health conditions in Europe.
One control of the designation and capacity of Notified Bodies, which the European	Considering this daunting situation, we call upon you, Mr. Vice-President, as responsible for ensuring
Commission and the mber States are still assessing to the new rules. It is only after being designated that	functioning EU internal market and temporarily also for public health, to take decisive action. I urge you
Notified B	utmost speed and urgency, and before the end of this Commission's mandate, to address this situation
typically take 3-9 months to complete a product re-certification, and it is expected that it will take them even	safeguard the continuity of patient care in the region and the sustainability of an SME-driven medical de
more time for new MDR certification. Tens of thousands of medical devices will have to undergo such a process, and May 2020 is 13 months away.	industry.
process, and way 2020 is 13 months away.	Considering the share to use of the sector
Furthermore, many product categories in the market, representing additional tens of thousands of devices, will	Considering the above, I would like to ask you for a meeting to discuss possible solutions on this matter.
be brought for the first time into the scope of Notified Body supervision. By May 2020, they will require MDR	Yours sincerely,
certification before they can continue to be used. At the current pace of preparation, the new regulatory system	
will not be ready early enough to absorb this extra workload. As of May 2020, thousands of medical devices will become any compliced and will not be authorized for use by ourgroups, destern become and patients.	
will become non-compliant and will not be authorized for use by surgeons, doctors, hospitals and patients.	
All new medical devices needing certification to access the European market will add on to the two points	

Serge Bernasconi Chief Executive Officer, MedTech Europe

MedTech Europe

The first indicate of the second second of the second seco

	Because THIS has barely changed in the past 18 months! Where we stand with the main 'building blocks' of the new regulatory system	
<u>where we stand wi</u>		
Implementing Acts:	2 are publishedbut at <i>least 16 more</i> are needed	
Guidance documents:	A few are donebut most are still to-do	
Expert panels:	None yet	
EU reference laboratories:	None yet	
Common specifications:	None yet	
Notified Bodies:	1 is notifiedin the <u>United Kingdom</u>	

Time is RUNNING OUT!

MDR

26 May 2020

= 12 calendar months from now

But really, we're out of time!

IVDR

26 May 2022

...and the IVD Regulation deadline is much closer than it seems!

Industry wants to comply, and will!



We have always **supported** the new system



But regulators must **enable** us to get products approved



We **cannot** submit files for review without **critical infrastructure**

Time is RUNNING OUT!

MDR

26 May 2020

= 12 calendar months from now

But really, we're out of time!

26 May 2022

...and the IVD Regulation deadline is much closer than it seems!

What is at stake



Patient care



Product supply to hospitals



Innovation



Small and medium-sized enterprises


	1 Notified Bodies: Designate them faster!
Our Call to Action for European	2 Re-certification : Ensure the procedure works for all products
Authorities	Eudamed : Deploy the new database with workable IT specifications and implementation timelines
	(Quality) Guidance: Publish it in the most urgent areas
Implement the new regulatory system	5 Scientific Bodies : Rapidly establish the new expert panels and EU reference laboratories
faster and with more efficiency:	6 Delegated and Implementing Acts : Publish the most-needed ones, including certain 'system-critical' common specifications
	7 Harmonised Standards: Ensure they are available in the highest- priority areas first

	Notified Bodies
	Designate them <u>faster</u> !
Problem	 <u>Virtually no</u> Notified Bodies (NBs) are available yet, and 26 May 2020 is 12 months away! Too few NBs are in the pipeline, and more are badly needed, especially for the <u>IVD sector</u> For those few NBs that are in the pipeline, designation is going <u>too slow</u>and industry is already experiencing certification <u>bottlenecks</u> and <u>delays</u> under the former Directives!
Our call to authorities	 Acknowledge that we are <u>not</u> on-track, and prepare for future insufficient NB availability Develop and communicate a coordinated, EU-wide solution that ensures that manufacturers can <u>continue CE marking</u>, even if they temporarily become 'orphans' Accelerate designation by removing as much <u>bureaucracy</u> from the process as possible
Deadline	 MDR: European solutions are needed <u>ASAP</u> to avoid potential market disruption! IVDR: Designations need to start in earnest from <u>mid-2019</u> onwards

	Re-certification
	Ensure the procedure works for <u>all</u> products
Problem	 Specific families of existing products are at special risk of becoming <u>unavailable</u>, e.g., Products <u>ineligible</u> for the 'grace period' that extends until May 2024 Products eligible for the grace period but unable to use it due to <u>insufficient</u> NB capacity
Our call to authorities	 Put in place a <u>staged</u> (re-)certification sequence for NBs to follow, e.g., giving priority to product families whose supply to the healthcare system are at exceptional <u>risk</u> Agree workable re-certification timelines and processes for existing 'combination products,' i.e., medical devices that incorporate ancillary <u>medicinal substances</u>
Deadline	A clear, actionable plan must be in place <u>by August 2019</u>


Problem	 Without a fully functional database, the Regulations' <u>benefits</u> would be severely reduced Some parts of the database are encountering <u>delays</u>, e.g., due to debates about whether existing devices should be (re-)registered in Eudamedand other parts are being <u>rushed</u>! Manufacturers need sufficient <u>time</u> to adapt their IT systems to Eudamed's technical specs
Our call to authorities	 Rapidly define and validate all Eudamed modules <u>needed</u> by May 2020 to apply the MDR If this cannot be achieved with clear, dependable timelines, publish <u>contingency guidance</u> so that stakeholders know how to proceed while Eudamed is still being built Only make the modules compulsory <u>18 months or more</u> after publishing stable IT specs Prioritise! Focus on delivering a fully functional database for <u>IVDR/MDR-certified</u> products
Deadline	 Actor registration module: Deploy it 'immediately' so we can start getting <u>SRNs</u>! UDI, device and certificate registration modules: 2nd priority. Deploy them <u>ASAP</u> Vigilance and clinical modules: Ensure <u>18 months minimum before</u> 'go live' date


	(Quality) Guidance
	Publish it in the most <u>urgent</u> areas
Problem	 <u>Many</u> (most) needed guidance documents are still to be published Some are as important as the 'core infrastructure' supporting IVDR/MDR implementation
Our call to authorities	 <u>MDR</u>: Publish ASAP guidance on software classification, Eudamed and UDI, transitional provisions, post-market surveillance (PMS), and on Article 61.6 ('sufficient clinical data') <u>IVDR</u>: Progress urgently with guidance on IVD classification, performance evaluation, conformity assessment, PMS, companion diagnostics and software-specific aspects
Deadline	 MDR: ASAP and ideally by <u>August 2019</u> IVDR: Everything must be published by <u>May 2020 latest</u> > Guidance on IVD classification is needed sooner, by <u>Q3 2019</u>



Delegated and Implementing Acts Publish the <u>most-needed</u> ones, including certain 'system critical' common specifications	
Problem	 Even the most 'mandatory' Acts are only starting to be published into <u>Year #3 of transition</u> Implementing Acts laying down <u>common specifications (</u>CS) are crucial for the conformity of some devices, e.g., Class D IVDs, and 'aesthetic' medical devices listed in MDR Annex XVI Manufacturers ideally need <u>many months</u> to adapt to the changes these Acts will bring
Our call to authorities	 Publish clear, ambitious <u>target deadlines</u> for developing and publishing all foreseen Acts Consider 'upgrading' the <u>priority</u> of certain Acts that are not currently in the Rolling Plan, e.g., the Act on free sale certificates, or the Act on implant card exemptions <u>Expedite</u> as much as possible the most-needed CS, e.g. ex-IVDD CTS → IVDR CS
Deadline	 Horizontal Acts – e.g., those needed to specify the roles and fees for expert panels – are needed ASAP and by no later than <u>August 2019</u> IVDR: CS need to be developed and published by <u>end 2019 (and no later than May 2020</u> MDR: CS on Annex XVI products are needed ASAP and by no later than <u>August 2019</u>
	Sector Se







Take-home Messages

To Industry

- Stay vigilant! These final months are going to be very tight, and much could still change
- Speak up! If you experience challenges, engage your Ministry of Health & competent authority to ensure your voice is heard!

To Authorities

- Please HURRY UP! It will soon be too late to deliver the regulatory system's most critical infrastructure, and <u>patient care</u> is at stake!
- Communicate! Industry needs to know <u>now</u> what steps you will take if the IVDR/MDR aren't successfully implemented on-time!

